Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stifel analyst Benjamin Burnett maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Hold and lowers the price target from $...
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate ...
Second IND Clearance for ATA3219 Following Non-Hodgkin's Lymphoma (NHL) and First in an Autoimmune Disease IndicationInitia...
ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (L...
